| ID | 1141 | |
| PMID | 16565728 | |
| Year | 2006 | |
| Sequence | ACSSSPSKHCG | |
| Name | TD-1 | |
| Length | 11 | |
| N-Terminal Modification | Free | |
| C-Terminal Modification | Free | |
| Linear/ Cyclic | Cyclic (C1-C9) | |
| Chirality | L | |
| Chemical Modification | None | |
| Origin of Peptide | De novo synthesis | |
| Nature of Peptide/Cargo | TD1 enhances the transdermal delivery of macromolecules | |
| Mechanism | TD1 overcomes the skin barrier by a distinct mechanism that most likely involves specific interactions between TD1 and unknown skin components | |
| Cargo Sequence/Structure | Not mentioned | |
| Name of cargo | Insulin-FITC | |
| Assay | Confocal Laser Scanning Microscopy, Blood glucose measurement | |
| Enhancer | None | |
| Properties of enhancer | Not applicable | |
| Concentration | Insulin-FITC (10 mg) with or without peptides (100 mg) was applied to the exposed abdominal skin of rats in a 100 ml volume made up by saline | |
| Incubation time | 24 h | |
| Tissue permeability (value with units) | Significant permeability of insulin could be seen in the confocal images, TD-1 without insulin had no effect on either blood glucose or serum insulin level, indicating that the glucose-lowering effect observed with TD 1 and insulin coadministration was due to the delivered exogenous insulin and not a physiological response elicited by TD-1 | |
| Tissue Sample | Abdominal skin of rat | |
| Ex vivo/In vivo/In vitro | in vitro | |
| STRUCTURE |
| |
| SMILES | N[C@@H](C)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC (=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O) CO)CO)CO)CCC2)CO)CCCC[NH3])Cc1nc[nH]c1)C(=O)NCC=O | |